Last reviewed · How we verify
cTACE
cTACE involves the direct injection of chemotherapy drugs into liver tumors via the hepatic artery.
cTACE involves the direct injection of chemotherapy drugs into liver tumors via the hepatic artery. Used for Hepatocellular carcinoma, Metastatic liver cancer.
At a glance
| Generic name | cTACE |
|---|---|
| Also known as | transarterial chemoembolization |
| Sponsor | Chengdu New Radiomedicine Technology Co. LTD. |
| Drug class | chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This approach allows for high concentrations of chemotherapy to be delivered directly to the tumor site, minimizing systemic side effects. The chemotherapy drugs used in cTACE are typically lipophilic and can be formulated to be released slowly over time, providing a sustained antitumor effect.
Approved indications
- Hepatocellular carcinoma
- Metastatic liver cancer
Common side effects
- Hepatotoxicity
- Fatigue
- Nausea and vomiting
- Abdominal pain
Key clinical trials
- Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC (NA)
- Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma (PHASE2)
- Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7 (PHASE3)
- MANDARIN (S6371) (PHASE3)
- A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC (PHASE2)
- DEB-TACE vs cTACE in HCC After TIPS (PHASE3)
- Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial. (PHASE2, PHASE3)
- A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cTACE CI brief — competitive landscape report
- cTACE updates RSS · CI watch RSS
- Chengdu New Radiomedicine Technology Co. LTD. portfolio CI